Assessment of Biochemical Determinants in Multiple Sclerosis Patients Following the Oral Administration of ß-D-Mannuronic Acid (M2000).
Curr Drug Discov Technol
; 18(5): e17092020186049, 2021.
Article
en En
| MEDLINE
| ID: mdl-32964823
ABSTRACT
BACKGROUND:
Multiple sclerosis is an autoimmune chronic inflammatory disease of the central nervous system that can lead to some serious disabilities. Despite using various immunomodulatory and anti-inflammatory drugs that have therapeutic effects, they cannot reduce its progression completely and have some unwanted side effects too. The immunomodulatory and anti-inflammatory effects of the ß-D-Mannuronic acid (M2000) have been proven in several surveys, and the present research was designed to determine its toxicity and therapeutic effects in MS patients.METHODS:
This study was performed on 15 MS patients who took 25 mg/kg/day the oral form of the ß-D-Mannuronic acid for six months, and 15 healthy people as a control group. Serum levels of Urea, Creatinine, GGT, Vitamin D3, Uric acid, and Anti-Phospholipids were compared to evaluate the therapeutic and possible toxic effects of this drug after this period.RESULTS:
Non- toxic effects through the study of urea, creatinine, GGT, and non-significant changes in uric acid and anti-Phospholipids levels, besides a significant rise in vitamin, D3 levels in the M2000 treated cases were found.CONCLUSIONS:
Our results suggested that ß-D-Mannuronic acid is a safe drug and has no toxicity when administered orally and also has some therapeutic effects in MS patients.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Esclerosis Múltiple
Límite:
Humans
Idioma:
En
Revista:
Curr Drug Discov Technol
Asunto de la revista:
FARMACOLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Irán